Health News Releases

June 15, 2020 17:37

Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders

Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE: 4502/NYSE:TAK) today announced a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE [

June 15, 2020 16:43

Marc Princen appointed new Global CEO for Mundipharma

FOR MEDICAL BUSINESS/TRADE MEDIA ONLY Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, e

June 15, 2020 11:15

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA)

June 12, 2020 13:55

Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter (OTC) and prescript

June 12, 2020 13:35

Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term c

June 11, 2020 14:00

Menarini Group Completes Acquisition of Stemline Therapeutics

Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage bi

June 09, 2020 09:24

New consortium EUbOPEN will provide tools to unlock disease biology

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and dis

June 08, 2020 11:25

Pegasus Development AG: Green Light for Multiple Production Sites Worldwide

Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastr

June 08, 2020 09:30

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis)

June 04, 2020 14:20

Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health

Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, i

June 03, 2020 11:38

Impossible Foods Wins Injunction in EU Trademark Infringement Case

A prominent European Union court granted Impossible Foods a preliminary injunction this week, ordering the global food conglomerate Nestlé S.A. to stop using the product name “Incredible Burger.” T

June 01, 2020 11:53

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an or

June 01, 2020 11:11

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society

June 01, 2020 10:35

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use

June 01, 2020 09:19

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a posi

June 01, 2020 09:02

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis[1]

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional ind

May 29, 2020 16:38

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP647

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeli

May 27, 2020 11:45

Smiths Medical Announces Ventilator Training Alliance App Partnership

Smiths Medical announced today it has joined several of the world’s other ventilator manufacturers in the Ventilator Training Alliance (VTA) to support frontline medical providers access to a centrali

May 27, 2020 10:57

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin f

May 25, 2020 11:11

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma ki

May 21, 2020 13:50

UAE Develops a Rapid Coronavirus Laser Testing Technology

QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company (IHC), announced that it has developed novel equipment which enables for much fast

May 19, 2020 10:22

Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga® (NewGam) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presented at AAN 2020

Octapharma has announced that results from the ProCID study were shared for the first time as a poster presentation during the virtual American Academy of Neurology (AAN) 2020 annual meeting. ProCID w

May 18, 2020 17:36

VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six (46) patient phase-II dose-ranging trial in

May 18, 2020 16:38

Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two u

May 18, 2020 11:11

European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuxima

News by Region

News by Industry